Can PET scans reveal which stomach cancers will respond to immunotherapy?
NCT ID NCT07824479
First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time
Summary
Researchers at Ruijin Hospital are testing two PET imaging tracers, FAPI and Grazytracer, to see if they can predict how well advanced gastric cancer responds to preoperative immunotherapy. The study enrolls 120 adults with resectable or advanced gastric cancer. Participants receive the tracers intravenously before PET/CT scans, and researchers compare imaging results with tumor regression after treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Two PET imaging tracers: FAPI and Grazytracer
- What this could lead to
- If the imaging works, doctors could tell early whether immunotherapy is shrinking a patient's gastric cancer, helping them adjust treatment sooner.
- What could go wrong
- The study is small and early. The imaging may not predict response accurately enough to guide treatment, and it adds an extra scan before surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
May 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Outpatients or inpatients who meet the eligibility criteria will be referred by the Department of Gastrointestinal Surgery at our hospital for enrollment in this clinical study.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age: 18 years ≤ age ≤ 80 years. 2. The subject must have histopathologically confirmed gastric adenocarcinoma via gastroscopic biopsy. 3. Clinical stage: cT3-4aN0-3M0 (according to the 8th edition UICC gastric cancer cTNM) with surgically resectable locally advanced gastric cancer, or cT3-4bN1-3M1 (non-peritoneal metastasis) with advanced gastric cancer. 4. Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1. 5. Hematology: white blood cell count \> 4 × 10⁹/L, neutrophil count \> 2 × 10⁹/L, hemoglobin \> 90 g/L, and platelet count \> 100 × 10⁹/L. 6. Cardiac function: left ventricular ejection fraction (LVEF) \> 50%. 7. Liver function: total bilirubin \< 1.5 × the upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 1.5 × ULN. 8. Renal function: serum creatinine ≤ 1.5 × ULN, or estimated glomerular filtration rate (eGFR) \> 60 mL/min. 9. The subject must agree to participate in this clinical trial and sign the informed consent form. 10. The subject must demonstrate good compliance, commit to adhering to the study procedures, and cooperate with the full implementation of the study process. 11. The subject must have no plans for pregnancy within 6 months. Exclusion Criteria: 1. Patients with other primary malignancies within 5 years, with the exception of adequately treated basal cell carcinoma and squamous cell carcinoma of the skin. 2. Patients with known hypersensitivity or contraindications to chemotherapeutic or immunotherapeutic agents. 3. Patients with severe concomitant diseases that, in the investigator's judgment, render the patient unsuitable for enrollment in this clinical study, including but not limited to severe cardiopulmonary insufficiency, severe bone marrow suppression, and severe hepatic or renal dysfunction. 4. Patients with severe psychiatric disorders, or those who are mentally impaired and unable to cooperate with the required study assessments. 5. Women who are pregnant, possibly pregnant, or breastfeeding. 6. Patients with poor compliance.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced gastric cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One small incision vs several: robotic stomach cancer surgery put to the test
- Can a direct hit to tumors make immunotherapy work better?
- Can a vaccine stop GI cancers from returning?
- Blood test aims to catch Cancer's return earlier
- Blood test guides immunotherapy for hidden cancer cells
- A targeted drug takes aim at a Hard-to-Treat stomach cancer